PTGX vs WY · rev $269.8M vs P/E 43, rev $3.59B
Protagonist Therapeutics Inc (PTGX) versus Weyerhaeuser Company (WY) — a side-by-side from cached financials, not a winner call.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Weyerhaeuser Company (WY) is a reit - specialty company listed on NYSE.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
Latest reported WY revenue for 2026-06-30 was $3.59B. Net income was $318.0M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
PTGX currently screens at market cap $7.25B. WY currently screens at market cap $17.54B and trailing P/E 43.4.
Not investment advice. Open the PTGX and WY stock pages for the full models.
Not investment advice.